Alexza Pharmaceuticals Inc.
Alexza Pharmaceuticals Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2000, the company has made significant strides in developing innovative therapies for central nervous system disorders, particularly focusing on acute and chronic conditions.
With a strong emphasis on its proprietary technology, Alexza has introduced unique products such as Adasuve, a fast-acting treatment for agitation associated with schizophrenia and bipolar disorder. This product exemplifies the company's commitment to enhancing patient care through rapid therapeutic interventions.
Recognised for its pioneering approach, Alexza Pharmaceuticals has established a solid market position, contributing to advancements in the treatment landscape. The company continues to explore new avenues for growth, aiming to address unmet medical needs in the pharmaceutical sector.
+25 vs industry average
Alexza Pharmaceuticals Inc.’s score of 63 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Alexza Pharmaceuticals Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Alexza Pharmaceuticals Inc. yet.
Alexza Pharmaceuticals Inc.'s reported carbon emissions
Alexza Pharmaceuticals Inc., headquartered in the US, currently does not have available carbon emissions data for the most recent year. As a result, specific figures regarding their total emissions, including Scope 1, Scope 2, and Scope 3 emissions, are not provided.
However, it is important to note that Alexza Pharmaceuticals Inc. is a current subsidiary of Grupo Ferrer Internacional, S.A. Consequently, any climate commitments or reduction initiatives may be influenced by the parent company's strategies. Unfortunately, there are no documented reduction targets or climate pledges from Alexza Pharmaceuticals Inc. at this time.
The absence of emissions data and reduction targets highlights the need for increased transparency and commitment to climate action within the pharmaceutical sector. As the industry moves towards more sustainable practices, it is crucial for companies like Alexza Pharmaceuticals Inc. to establish clear climate goals and report their emissions data to align with global sustainability efforts.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Alexza Pharmaceuticals Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Alexza Pharmaceuticals Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative
Inherited from Grupo Ferrer Internacional, S.A.
Carbon Disclosure Project
Inherited from Grupo Ferrer Internacional, S.A.The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project